

RECEIVED

DEC 15 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1652
FRIDKIN et al)	Examiner: R. Hutson
Appln. No. 09/117,380)	Washington, D.C.
Filed: January 27, 1999)	December 12, 2000
For: ANTI-INFLAMMATORY PEPTIDES))	Atty.Docket: FRIDKIN=1
DERIVED FROM C-REACTIVE)	
PROTEIN)	

13/B
D.G.
12/18/00

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 12, 2000, please amend the present application as follows:

IN THE CLAIMS

Rewrite claim 1 in amended form as follows:

1 (Amended). [A] An isolated peptide capable of inhibiting *in vitro* the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being selected from:

(i) a core peptide [corresponding] identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula:

Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (of SEQ ID NO:3)

or a modification thereof characterized by:

B'
sub
C1

GP 1652

UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: FRIDKIN et al

Application No.: 09/117,380

Filed: January 27, 1999

For: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN

Art Unit: 1652

Examiner: R. Hutson

Washington, D.C.

Atty.'s Docket: FRIDKIN=1

Date: December 12, 2000

RECEIVED

DEC 15 2000

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Transmitted herewith is a [XX] Amendment [...]

in the above-identified application.

☐ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.☒ No additional fee is required.☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 11	MINUS	** 20	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY

RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	

OR

OTHER THAN SMALL ENTITY

RATE	ADDITIONAL FEE
x 18	\$
x 80	\$
+ 270	\$
TOTAL	

OR

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$ 195.00
☐ Third - \$ 445.00
☐ Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 390.00
☐ Third - \$ 890.00
☐ Fourth - \$ 1390.00


Month After Time Period Set

☐ Less fees (\$) already paid for ___ month(s) extension of time on _____.☐ Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.☐ A check in the amount of \$ _____ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
 ROGER L. BROWDY
 Registration No. 25,618

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197